Trial Profile
Rotigotine for the treatment of Parkinson's disease, the experience of a tertiary Movement Disorder centre after 1 year of approval by Health Canada.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Aug 2015
Price :
$35
*
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 14 Aug 2015 New trial record
- 18 Jun 2015 Results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.